secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0001104659-23-105928
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx discontinues Phase 2b ibezapolstat trial early on high cure rates, no safety concerns; Phase 3 accelerated
--------------------------------------------------------------------------------

- Phase 2b discontinued after blinded data showed high clinical cure rates for ibezapolstat and vancomycin, with no emerging safety concerns.
- Company expects to advance ibezapolstat to Phase 3 more expeditiously; topline efficacy results to be reported promptly.
- Ibezapolstat is first-in-class, FDA QIDP/Fast-Track-designated antibiotic for C. difficile infection, potentially first new antibiotic class in 30+ years.
- Decision also influenced by site maintenance costs and slow enrollment due to COVID-19; Independent Data Monitoring Committee will not perform interim analysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465923105928/0001104659-23-105928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465923105928/tm2327257d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-105928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer